http://glioblastomatreatments.wiki:80/index.php
type: Ontology
creation date: 2026-08-27T01:38:23-07:00
imports: http://semantic-mediawiki.org/swivt/1.0

MN-166
type: Subject
type: http://glioblastomatreatments.wiki/index.php
page: http://glioblastomatreatments.wiki:80/index.php
wiki namespace: 0
wiki page content language: en
has OS with: http://glioblastomatreatments.wiki/index.php
has OS without: http://glioblastomatreatments.wiki/index.php
has PFS with: http://glioblastomatreatments.wiki/index.php
has PFS without: http://glioblastomatreatments.wiki/index.php
has toxicity explanation: MN-166 has a well-documented safety profile with low toxicity. It is generally well-tolerated, though mild gastrointestinal symptoms and fatigue may occur. No unexpected adverse effects have been reported in glioblastoma or ALS clinical trials.
has toxicity level: http://glioblastomatreatments.wiki/index.php
has usefulness rating: http://glioblastomatreatments.wiki/index.php
has clinical trial phase: http://glioblastomatreatments.wiki/index.php
has common side effects: http://glioblastomatreatments.wiki/index.php
has original text: http://glioblastomatreatments.wiki/index.php
has treatment name: http://glioblastomatreatments.wiki/index.php
processing error: http://glioblastomatreatments.wiki/index.php
wiki page modification date: 2025-02-24T02:58:12Z
modification date#aux: 2460730.62375
wiki page sort key: MN-166

http://glioblastomatreatments.wiki/index.php
type: Subject
master page: MN-166
wiki namespace: 0
has improper value for: http://glioblastomatreatments.wiki/index.php
processing error message: [2,"smw-datavalue-wikipage-property-invalid-title","Has clinical trial explanation","In glioblastoma, a Phase 1b\/2a trial evaluated MN-166 in combination with temozolomide (TMZ), showing it was safe and well-tolerated. Progression-Free Survival at 6 months (PFS6) was 44% in newly diagnosed patients and 31% in recurrent cases, with the latter improving over historical controls. MN-166 is also in a Phase 2b\/3 trial for ALS (COMBAT-ALS), where interim analysis suggests it may slow disease progression. The trial is ongoing, with top-line data expected in 2026."]
wiki page sort key: MN-166# ERR3019b4979f53631ee3912d6416218f93

http://glioblastomatreatments.wiki/index.php
type: Subject
master page: MN-166
wiki namespace: 0
has improper value for: http://glioblastomatreatments.wiki/index.php
processing error message: [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","MN-166 shows promise in glioblastoma when combined with temozolomide, with clinical trials indicating improved progression-free survival. It has demonstrated potential in slowing neurodegenerative disease progression (ALS, MS, DCM) and is undergoing further clinical validation."]
wiki page sort key: MN-166# ERR0de0b09fdf871942cb9b8a10a8978dce